USA - NASDAQ:ARNA - Common Stock
We assign a fundamental rating of 2 out of 10 to ARNA. ARNA was compared to 534 industry peers in the Biotechnology industry. ARNA has a bad profitability rating. Also its financial health evaluation is rather negative. ARNA does not seem to be growing, but still is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -78.55% | ||
| ROE | N/A | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | -1141511.11% | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 27.53 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.59 | ||
| Quick Ratio | 8.59 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -10.44 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
99.99
+0.06 (+0.06%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 114173.77 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 9.16 | ||
| P/tB | N/A | ||
| EV/EBITDA | -10.44 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -78.55% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | -1141511.11% | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.59 | ||
| Quick Ratio | 8.59 | ||
| Altman-Z | 27.53 |
ChartMill assigns a fundamental rating of 3 / 10 to ARNA.
ChartMill assigns a valuation rating of 1 / 10 to ARENA PHARMACEUTICALS INC (ARNA). This can be considered as Overvalued.
ARENA PHARMACEUTICALS INC (ARNA) has a profitability rating of 0 / 10.
The Earnings per Share (EPS) of ARENA PHARMACEUTICALS INC (ARNA) is expected to grow by 2.6% in the next year.